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Abstract
Background: Postvaccination fever is a mild adverse event that naturally improves without complications, but is highly prevalent
and can be accompanied by febrile convulsions in some cases. These adverse effects may cause parents to delay or avoid vaccinating
their children.
Objective: This study aimed to identify postvaccination fever patterns and the ability of antipyretics to affect changes in these
patterns from data collected from a mobile app named Fever Coach.
Methods: Data provided by parents of feverish children derived from a mobile app, Fever Coach, were used to identify
postvaccination fever patterns according to vaccinations and the use of antipyretic drugs. We selected single vaccination records
that contained five or more body temperature readings performed within 48 hours of vaccination, and we analyzed postvaccination
fever onset, offset, duration, and maximum body temperature. Through observing the postvaccination fever response to vaccination,
we identified the effects of antipyretic drugs on postvaccination fever onset, offset, and duration times; the extent of fever; and
the rate of decline. We also performed logistic regression analysis to determine demographic variables (age, weight, and sex)
involved in relatively high fevers (body temperature ≥39°C).
Results: The total number of Fever Coach users was 25,037, with 3834 users having entered single vaccination records, including
4448 vaccinations and 55,783 body temperature records. Most records were obtained from children receiving the following
vaccinations: pneumococcus (n=2069); Japanese encephalitis (n=911); influenza (n=669); diphtheria, tetanus, and pertussis
(n=403); and hepatitis A (n=252). According to the 4448 vaccination records, 3427 (77.05%) children had taken antipyretic drugs,
and 3238 (89.15%) children took antibiotics at body temperatures above 38°C. The number of children taking antipyretics at a
body temperature of 38°C was more than four times that of those taking antipyretics at 37.9°C (307 vs 67 cases). The number of
instances in which this temperature threshold was reached was more than four times greater than the number when the temperature
was 37.9°C. A comparative analysis of antipyretic and nonantipyretic cases showed there was no difference in onset time; however,
offset and duration times were significantly shorter in nonantipyretic cases than in antipyretic cases (P<.001). In nonantipyretic
cases, offset times and duration times were 9.9 and 10.1 hours shorter, respectively, than in antipyretic cases. Body temperatures
also decreased faster in nonantipyretic cases. Influenza vaccine-associated fevers lasted relatively longer, whereas pneumococcus
vaccine-associated fevers were relatively short-lived.
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Conclusions: These findings suggest that postvaccination fever has its own fever pattern, which is dependent on vaccine type
and the presence of antipyretic drugs, and that postvaccination temperature monitoring may ease fever phobia and reduce the
unnecessary use of antipyretics in medical care.
(JMIR Mhealth Uhealth 2019;7(4):e12223)   doi:10.2196/12223
KEYWORDS
patient-generated health data; vaccination; postvaccination fever; digital health care; mobile app
Introduction
The World Health Organization and the Korean Centers for
Disease Control and Prevention recommend at least 10 and 14
vaccines, respectively, for routine immunization of children [1].
Despite benefits in preventing serious infectious diseases,
vaccinations are also associated with a risk of adverse events
in patients. Fever is the most commonly reported adverse event
[2,3]. The immune system’s lymphocyte and polymorphonuclear
leukocyte functions improve at body temperatures between
38°C and 39°C. Therefore, the presence of postvaccination fever
indicates that the immune system is functioning, but not due to
a pathologic reaction [4-6]. There is no agreed definition of a
postvaccination fever, but the gold standard definition of a fever
is a rectal temperature of 38°C or above. Several studies report
varying timeframes for postvaccination fever, ranging from
within 32 hours, 48 hours, and 4 days of vaccination [7-9].
Postvaccination fever is a mild adverse event that is usually
self-limiting over a few days without any specific complications.
However, it is highly prevalent and, in some cases, accompanied
with febrile convulsions. Furthermore, postvaccination fever
may serve as an indicator of infectious disease. For these
reasons, postvaccination fever can cause excessive anxiety in
parents and caregivers [10-12]. Previous studies have indicated
that parent perceptions and fear of fever have not significantly
changed over the past 20 years and are still common in the
Korean population [13-15]. Postvaccination fever phobia could
lead to unnecessary testing, treatment (including the overuse of
antipyretics), and emergency department visits, which increase
both medical costs and the possibility of side effects [7,16].
Although fever can occur after every vaccination, a higher
incidence of fever has been observed in patients receiving
pneumococcal and DTaP (diphtheria, tetanus, and pertussis)
vaccines than in those receiving other vaccines [17-19],
indicating that fever patterns appear to be vaccine-specific.
Many febrile diseases have specific fever patterns and
progression (continuous, intermittent, remittent) that aid in
understanding the pathophysiology of each disease and help to
make diagnoses and therapeutic judgments [20,21]. Therefore,
knowing the pattern and progress of postvaccination fever is
likely to help address issues due to misperceptions regarding
vaccination. There have been studies reporting on
postvaccination fever frequency, but relatively few studies have
reported postvaccination fever patterns [3,20-24]. However,
many typical fever patterns can be changed through ingestion
of antipyretics such as acetaminophen and steroidal
anti-inflammatory drugs. The principal action of these drugs is
inhibition of the enzyme cyclooxygenase and reduction of the
levels of prostaglandin E2 within the hypothalamus [25].
However, data regarding postvaccination fever patterns and
progress are difficult to obtain, with most postvaccination
fever-related medical care occurring in outpatient settings where
accurate body temperature recordings are not easily obtainable.
Patient-generated health data (PGHD) acquired through
high-mobility mediums such as mobile phones, Internet of
Things, wearable devices, and mobile apps have recently
emerged as alternative methods for collecting data [26-31].
Some studies have shown that these PGHD have improved
patient treatment, and studies are underway regarding how
PGHD can be linked to routine treatment [32,33]. With
immunization, however, obtaining longitudinal and continuous
data is difficult. This study aimed to investigate the fever
patterns of postvaccination fever through retrospectively
analyzing PGHD obtained using Fever Coach, a fever
management mobile app, and to analyze changes in fever
patterns with the use of antipyretics.
Methods
Mobile App Description
Fever Coach is a mobile health care app developed by Mobile
Doctor for parents with a feverish child. The app is based on
pediatric thermal standards; it assesses a child’s condition based
on user input and provides guidelines for antipyretic use. The
app provides services that support parents’ effective and accurate
control of common fever symptoms. Fever Coach provides
several data services related to managing fever in children, such
as microdust concentration status, body temperature information
depending on geographical area, disease epidemic alerts, and
pediatric health information. The app was made available as a
free download from the Google Play Store and Apple App Store.
As of June 31, 2017, 197,555 people had registered their child
with the app.
We collected vaccination records and records of subsequent
postvaccination fever responses and the antipyretics
administered. Figure 1 shows the detail screens of the Fever
Coach app and the types of data users can enter. All screens of
Fever Coach are in Multimedia Appendix 1. The “Today’s
Records” function provides information for vaccination records.
The “Enter the Temperature” function allows the user to provide
data concerning the fever response. The “Enter the Dose”
function allows the user to provide records of antipyretic use.
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Figure 1. Screenshots of vaccination and fever response in the Fever Coach app. The left screen (“Today’s Records”), middle screen (“Enter the
temperature”), and right screen (“Enter the dose”) have areas for user-input data. The functions corresponding to vaccination data, fever response, and
antipyretic data in the three screens are indicated with dotted boxes. The original app showed Korean menu names; for international use, they have been
translated into English.
Study Design
To identify vaccination and antipyretic effects on
postvaccination fever response patterns, we analyzed the logs
of all users who signed up and registered their child between
July 2015 and June 2017. Postvaccination fever usually lasts
less than 48 hours [34]; therefore, we examined fever response
and antipyretic administration data for 48 hours after the
vaccination date entered by the user. For postvaccination fever
response analyses, we defined the onset of fever as the point
when the body temperature exceeded 38.0°C, and the offset as
the point when the body temperature fell below 38.0°C [35,36].
Onset time was defined as the time between vaccination and
the point at which body temperature exceeded 38.0°C. If the
first record was above 38.0°C, the time from vaccination to the
registration of the data was defined as the onset time. Similarly,
offset time was defined as the time between vaccination and the
last point at which the body temperature fell below 38.0°C. The
duration time was defined as the time elapsed between onset
and offset points (Figure 2). Body temperature values were
obtained using linear imputation techniques when they were
missing between two actual body temperatures in the neighbors
(Figure 2). We used this linear imputation technique on the
assumption that the fever progression would show linear
characteristics.
This study was approved by the Institutional Review Board of
the Asan Medical Center (IRB no. 2018-0179; Seoul, South
Korea). The need for informed consent was waived by the Ethics
Committee because this study used routinely collected log data
that were anonymously managed at all stages, including during
data cleaning and statistical analyses.
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Figure 2. Onset, offset, and duration time definitions. The x-axis represents the time since vaccination and the y-axis represents the body temperature.
The blue dot represents the actual body temperature. The black line between the blue dots is the imputated body temperature.
Data Collection and Analysis
The app allows users to enter data regarding vaccinations, body
temperatures, and antipyretic drug administration history. The
vaccination record consists of the type and time of vaccine given
to a particular child. The body temperature record consists of
body temperature and measurement time for a specific child.
The antipyretic drug administration record consists of antipyretic
agent type, dose, and time. Figure 3 shows the target population
selection flow of the study. From July 2015 to June 2017, 65,894
vaccination records were entered, of which 64,003 were
vaccination records with basic user information (sex, weight,
and age). Among them, the number of single vaccination records
was 15,538. To obtain a sufficient number of body temperature
recordings and significant onset and offset values, these data
were filtered into 5949 cases with at least five body temperatures
recorded within 48 hours after vaccination. Of these, 4448
comprised data-containing points corresponding to onset and
offset times. Among these data, bacillus Calmette-Guérin,
hepatitis B, measles-mumps-rubella (MMR),
Haemophilusinfluenzae type B (Hib), polio, rotavirus, and
chickenpox were excluded from the analysis because the number
of vaccination records was less than 100; therefore, only data
regarding DTaP, Japanese encephalitis, pneumococcus, hepatitis
A, and influenza were analyzed. Although DTaP and MMR
vaccines are combination vaccines, we considered these
combination vaccines to be single vaccinations because they
are single shots that can be distinguished from multiple
vaccinations that involve multiple shots and that vaccines
contain a variety of ingredients that can cause side effects [37].
The analysis was undertaken by grouping the data into 3238
cases with antipyretic records and 982 cases with no antipyretic
records. For each vaccination record, the sex and age of the
child were also collected.
To confirm the postvaccination fever differences between
vaccination and antipyretic drug administration, we performed
statistical analysis. To compare differences in onset times, offset
times, duration times, and maximum temperatures, an
independent sample t test was used to determine the degree of
difference, while the P value for a two-sided test was used to
test for significance. To observe the process of fever for each
vaccine record, the onset time was defined as reference time 0,
and body temperature values recorded over the previous 3 hours
and the following 24 hours were obtained. Cases were grouped
according to whether they were given antipyretic drugs and
were reclassified according to vaccine type. Additionally, an
ANOVA test was performed to compare maximum temperature
and fever duration among the vaccine types. We used a Dunnett
T3 post hoc test because the P value of the Levene test was less
than .001, which indicated a violation of the assumption of
homogeneity of variance. Lastly, binary logistic regression
analysis was performed to determine demographic variables
(age, weight, and sex) involved in relatively high fevers (body
temperature ≥39°C). We performed multiple regression tests to
identify multicollinearity between age and weight. If the variance
inflation factor (VIF) was less than 10, it was considered that
there was no multicollinearity for those variables. Data were
processed and analyzed using R version 3.5.0, SPSS 21.0, and
Python 3.6 (including packages of Pandas 0.22.0, NumPy 1.14.3,
and Jupyter 1.0.0).
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Figure 3. Data collection flowchart.
Results
Overall Characteristics
During the 24 months of the Fever Coach operation, a total of
25,037 users recorded 65,894 vaccinations involving 387,613
body temperature records for 25,608 children. Of the 64,003
vaccination records for which a child’s basic information was
available, 15,538 (24.27%) were single vaccination records. Of
the total number of enrolled children, there were 3834 (14.97%)
children with five or more body temperature records at onset
and offset, with 4448 vaccination records and 55,783 body
temperature records (Table 1). The age at vaccination was
significantly different in relation to the vaccine types. The
proportion of males in this study was 60.12% (2193/3648). The
proportion of vaccination records with antipyretic drugs was
77.05% (3427/4448). The majority of records were from children
receiving the following vaccinations: pneumococcus (n=2069),
Japanese encephalitis (n=911), influenza (n=669), DTaP
(n=403), and hepatitis A (n=252). Each of the remaining single
vaccinations had less than 100 records each.
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Table 1. Basic characteristics according to vaccine type and the presence of antipyretic drugs.
Body temperature (°C)Body tempera-
ture records,
mean (SD)
Vaccination
records with
antipyretics,
n (%)
Weight (kg)Sex (male),
n (%)
Age (months)Type of vaccination
(number of records,
number of children) Mean
(SD)
Median
(IQR)
Mean (SD)Median
(IQR)
Mean
(SDb)
Median
(IQRa)
37.6 (0.8)37.7 (0.9)10.3 (5.0)10 (62.5)8.6 (3.7)7.7 (15.0)8 (61.5)13.1 (13.3)6.6 (21.5)BCGc (16, 13)
38.1 (0.8)38.1 (1.0)14.0 (7.7)29 (93.5)11.3 (4.7)10.1 (35.0)19 (67.9)18.6 (12.3)14.3 (6.2)Chickenpox (31, 28)
37.9 (0.7)37.9 (0.8)12.7 (7.2)318 (80.7)9.5 (3.1)9.5 (27.8)212 (60.2)14.9 (13.0)13.3 (14.8)DTaPd (394, 352)
37.9 (0.7)37.9 (0.9)12.1 (9.2)54 (88.5)9.7 (3.7)9 (22.3)37 (67.3)14.5 (14.4)10.7 (7.3)Hepatitis B (61, 55)
38 (0.7)38 (1.0)14.3 (9.8)229 (92.7)11 (1.6)11 (16.0)130 (58.3)20.4 (6.2)19.8 (9.1)Hepatitis A (247, 223)
37.9 (0.7)37.9 (0.9)12.1 (5.9)43 (91.5)9.4 (2.0)9.7 (15.0)20 (50.0)14.4 (6.0)15.3 (9.1)Hibe (47, 40)
38 (0.8)38 (0.9)13.3 (8.1)576 (87.9)12.5 (4.3)11.5 (39.0)325 (55.4)28 (20.8)17.2 (7.9)Influenza (655, 587)
37.9 (0.7)37.9 (0.8)12.0 (7.5)792 (89.0)10.7 (1.8)10.4 (23.5)422 (53.2)19.1 (8.1)17.2 (7.9)Japanese encephalitis
(890, 793)
38.1 (0.8)38.1 (1.1)13.3 (6.2)29 (93.5)11.9 (2.8)11 (19.0)15 (53.6)23.4 (15.8)16.1 (10.0)MMRf (31, 28)
37.8 (0.6)37.7 (0.7)12.3 (7.7)1323 (65.0)8.2 (2.5)8 (32.0)981 (55.5)9.3 (8.1)7.1 (11.0)Pneumococcus (2034,
1771)
37.7 (0.7)37.7 (0.7)11.5 (6.5)11 (57.9)9.3 (2.7)8.8 (14.0)11 (64.7)12.1 (9.2)12.3 (11.2)Polio (19, 17)
37.7 (0.5)37.7 (0.9)9.6 (5.1)13 (56.5)7.1 (1.7)7 (11.5)13 (59.1)5.5 (3.1)5.2 (4.4)Rotavirus (23, 22)
37.9 (0.7)37.7 (0.7)12.5 (7.8)3427 (77.0)9.7 (3.2)9.7 (3.5)2193 (60.1)15.4 (13.3)13.5 (13.0)Total (4448, 3648)
aIQR: interquartile range.
bSD: standard deviation.
cBCG: bacille Calmette-Guérin.
dDTaP: diphtheria, tetanus, pertussis.
eHib: Haemophilusinfluenzae type b.
fMMR: measles, mumps, and rubella.
Antipyretic Drug Administration Pattern
After vaccination, 14.66% (475/3238) of children were
administered the first antipyretic drug within 1 hour, and more
than 50% of children were administered antipyretic drugs within
10 hours. By 10 hours, the number of children treated with
antipyretic drugs increased gradually, but decreased from 11
hours to less than 10% at 41 hours. A total of 2887 (89.16%)
children used antipyretics when the postvaccination body
temperature was 38.0°C or above (Figure 4). The number of
children taking antipyretics at a body temperature of 38°C was
more than four times that of those taking antipyretics at 37.9°C
(307 vs 67 cases). The percentages of children who received
antipyretic drugs were 0.71% (23/3238) and 0.49% (16/3238)
at body temperatures lower than 37°C and above 40°C,
respectively.
Comparison of Onset, Offset, and Duration Times
Among Vaccination Records With and Without
Antipyretic Administration
There were significant differences in offset times, duration
times, and maximum temperatures between groups that had
taken antipyretics and those that had not, but there was no
significant difference in onset times (Figure 5). Differences
between groups were marked, especially maximum temperatures
that affected offset time and duration. Children vaccinated
against hepatitis A showed the greatest difference in maximum
temperature (mean 39.0ºC, SD 0.6ºC vs mean 38.4ºC, SD 0.4ºC
in children who had been administered antipyretic drugs
compared to children who had not been administered antipyretic
drugs). The postvaccination fever duration was three times
longer in children who were administered antipyretic drugs than
in children who were not administered antipyretic drugs (mean
17.4, SD 11.8 hours vs mean 4.9, SD 7.5 hours, with antipyretic
drugs compared to without antipyretic drugs).
Postvaccination fever differences between onset, offset, and
duration times associated with each vaccine showed statistically
significant differences in offset times and duration between
groups (P<.001) (Multimedia Appendix 2). Offset and duration
times for children who were not administered antipyretics were
significantly shorter than for those who were administered
antipyretics. There was no significant difference in onset time
between the groups.
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Figure 4. Time of first administration of antipyretic after vaccination and body temperature at the time of antipyretic use.
Figure 5. Comparison of onset, offset, duration times, and maximum temperatures among vaccine types, and the effects of antipyretics on postvaccination
fever response. From left to right: box plots of onset, offset, duration times, and maximum body temperature are depicted. The bar indicates the median;
x indicates the mean.
We found statistically significant differences in maximum
temperature and fever duration among vaccines (both P<.001).
In the postanalysis grouping, maximum temperature and fever
duration decreased in the following order: hepatitis A, influenza,
Japanese encephalitis, DTaP, and pneumococcus (Table 2).
We used logistic regression to determine the demographic
variables involved in relatively high fevers (Table 3). There
was no multicollinearity between age and weight (age VIF=4.38,
weight VIF=4.38). Sex was not a significant variable in all
groups, and age was not significant except in children who were
administered the pneumococcus vaccine. Weight was statistically
significant in all cases except in those receiving the hepatitis A
vaccine.
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Table 2. Comparison of maximum temperature and fever duration among vaccine types.
P valueaF 4,4215Mean (SD)Vaccine type
<.00194.7Maximum temperature (°C)
38.5 (0.5)Pneumococcus
38.7 (0.6)DTaP
39.0 (0.6)Hepatitis A
38.9 (0.6)Influenza
38.8 (0.5)Japanese encephalitis
<.00162.8Fever duration (hours)
8.5 (10.5)Pneumococcus
11.3 (11.1)DTaP
16.4 (12.0)Hepatitis A
14.6 (12.3)Influenza
12.8 (11.7)Japanese encephalitis
aAs a result of the post hoc test (Dunnett T3), maximum temperature and fever duration showed the following: Hepatitis A, influenza > Japanese
encephalitis, DTaP > pneumococcus.
Table 3. Variables involved in relatively high postvaccination fever (≥39°C).a
Adjusted odds ratio (95% CI)P valueB (SE)Vaccine type and variable
Pneumococcus
1.057 (1.029-1.086)<.0010.056 (0.014)Age
1.233 (1.135-1.340)<.0010.210 (0.042)Weight
0.908 (0.716-1.152).42–0.096 (0.121)Sex
DTaP
0.996 (0.960-1.033).82–0.004 (0.018)Age
1.263 (1.075-1.485).0050.234 (0.083)Weight
0.718 (0.457-1.129).15–0.331 (0.231)Sex
Japanese encephalitis
1.006 (0.984-1.029).590.006 (0.012)Age
1.114 (1.005-1.234).030.108 (0.052)Weight
0.933 (0.706-1.233).62–0.070 (0.142)Sex
Hepatitis A
1.037 (0.989-1.088).130.036 (0.024)Age
1.011 (0.841-1.217).900.011 (0.094)Weight
1.171 (0.698-1.966).550.158 (0.264)Sex
Influenza
0.984 (0.966-1.003).09–0.016 (0.010)Age
1.109 (1.102-1.216).020.104 (0.047)Weight
1.002 (0.732-1.372).980.002 (0.160)Sex
All
0.996 (0.985-1.007).43–0.004 (0.006)Age
1.254 (1.195-1.316)<.0010.226 (0.025)Weight
0.899 (0.782-1.034).13–0.106 (0.071)Sex
aCI: confidence interval; DTaP: diphtheria, tetanus, pertussis; SE: standard error.
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Figure 6. Body temperature graph over time for each vaccine showing the effects of antipyretic administration. The empty circle indicates the mean;
the error bar represents a 95% confidence interval.
Comparison of Fever Response
Figure 6 shows the result of plotting body temperature over
time for each vaccine type and the effects of antipyretic drug
administration. In cases where antipyretics were not
administered, especially concerning DTaP and pneumococcus,
the slope of the graph was steeper than in cases that included
antipyretics, indicating that body temperature dropped more
rapidly in children who were not administered antipyretic drugs
(DTaP R2: .84 vs .00; pneumococcus R2: .83 vs .14). In the
antipyretic use group, the mean body temperature was 37.5°C
or above even after 24 hours, but in the nonantipyretic use group,
the mean body temperature dropped below 37.5°C before 20
hours for all vaccines except hepatitis A. In comparing vaccines,
we found that postvaccination fever associated with the influenza
vaccine tended to be relatively long-lasting, and that the
pneumococcus vaccine showed a relatively rapid decline.
Comparison of the Effects of Antipyretics on
Postvaccination Fever Response
Multimedia Appendix 2 shows the comparison of onset, offset,
duration times, maximum temperatures among vaccine types,
and the effects of antipyretics on postvaccination fever response.
Postvaccination fever in children who were administered
antipyretics exhibited a mean onset time of between 9.0 and
13.7 hours, a mean offset time of between 20.4 and 31.1 hours,
a mean duration time of between 11.5 and 17.4 hours, and a
maximum temperature of between 38.7°C and 39°C. The mean
postvaccination fever onset time was not significantly different
between children who were administered antipyretics and those
who were not (mean 10.9, SD hours 9.9 vs mean 10.4, SD hours,
9.3 P=.12), but the mean offset time and duration were
significantly different (offset time: mean 24.3, SD hours 13.4
vs mean 13.6, SD 9.9 hours, P<.001; duration: mean 13.4, SD
11.9 hours vs mean 3.2, SD 5.0 hours, P<.001). The maximum
body temperatures at onset time were mean 38.8°C (SD 0.6°C)
in the antipyretic group and mean 38.3°C (SD 0.5°C) in the
nonantipyretic group, with a statistically significant difference
between the two groups (P<.001).
Discussion
Principal Findings
We identified different postvaccination fever responses for each
vaccine using data collected through the mobile app Fever
Coach. For example, in relation to the hepatitis A vaccine, the
postvaccination fever maximum temperature was statistically
significantly higher and was of a longer duration than that for
other vaccines (P<.001). We were also able to clearly identify
differences among postvaccination fevers with and without
antipyretic administration; offset, duration times, and maximum
temperature were significantly different between groups
(P<.001). Additionally, we presented new evidence from
large-scale PGHD concerning fever duration and maximum
temperatures reached after a single vaccination. The
postvaccination fever duration was generally 48 hours but, for
all single vaccinations, the longest postvaccination fever duration
was mean 16.4 (SD 12.0) hours, and the highest maximum
temperature was mean 39.0°C (SD 0.6°C). In terms of
informatics, an additional contribution of this study is that the
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majority of users verified the pediatric fever level based on the
PGHD. This study is original compared with previous studies
for the following reasons: we used actual postvaccination fever
response data without any clinical intervention; we analyzed
large-scale postvaccination fever responses based on real-world
data rather than relying on data from a small, clinical-based
group; and our study used data derived from anyone using a
mobile phone and not just from a specific hospital or specific
patient area, which allowed us to analyze individual data
covering a larger area than from data from a single institution
or specific area.
Characteristics of Postvaccination Fever and Its
Natural Course According to Vaccine Type
Because most previous studies have been conducted to determine
vaccine safety, they primarily discussed the frequency and
severity of postvaccination fever and did not provide medical
direction to parents or caregivers. This study showed that
postvaccination fever associated with each vaccine has a unique
fever pattern in terms of maximum temperature and duration.
Among all vaccines included in the study, the postvaccination
fever in the nonantipyretic use group showed a mean onset time
of 9.4 hours (pneumococcal vaccine) to 15.3 hours (hepatitis A
vaccine), a mean offset time of 12.5 hours (pneumococcal
vaccine) to 20.1 hours (hepatitis A vaccine), and a mean duration
time of 2.5 hours (DTaP vaccine) to 6.1 hours (influenza
vaccine) (details in Multimedia Appendix 2). These values are
considered consistent with associated fever and vaccination
administration if the fever occurs within 24 hours of vaccination
and if the temperature falls within 24 hours after onset in general
practice [38]. The characteristics of postvaccination fever
according to vaccine type in all data were as follows: the
maximum temperature was highest for children vaccinated
against hepatitis A and lowest for children receiving the
pneumococcal vaccine. Children receiving the pneumococcal
vaccine are known to have a high incidence of postvaccination
fever; therefore, it is not uncommon for clinical practitioners to
give a warning before and after vaccination and recommend
that parents administer antipyretic agents when fever occurs
[19,39]. However, the results of this study showed that the mean
temperature following pneumococcal vaccination was
significantly lower than for other vaccinations, regardless of
the use of antipyretics. Fever duration was longest for hepatitis
A and influenza, followed by Japanese encephalitis,
pneumococcus, and DTaP vaccine. Postvaccination fever
associated with pneumococcal vaccine had a lower maximum
temperature and a shorter duration than postvaccination fever
associated with hepatitis A vaccine but fell below the fever onset
temperature (38°C) within 24 hours after fever occurred. If
parents were more aware of this natural course of
postvaccination fever, they may be less anxious and reduce the
use of antipyretics, thereby reducing unnecessary medical care
[40,41]. We would expect parents to have a more positive
outlook regarding vaccinations once their fears concerning fever
had been more fully addressed [15].
Our results showed that, as a child’s weight increased, there
was a high probability that a relatively high fever with a body
temperature of less than 39°C would occur, regardless of age
or sex (Table 3). It is known that the incidence of fever
(especially a high fever with a body temperature of 39°C) tends
to increase in children receiving the pneumococcal booster
vaccination after 1 year of age, which is thought to be due to
the booster effect, as the immune function matures and the
number of vaccinations increase with age [24]. Here, however,
only weight was significantly associated with the risk of high
fever. Generally, a child’s age and weight are linearly correlated.
The immune response to vaccination is known to be higher for
girls than for boys [42,43], but there was no difference in the
frequency of relatively high fevers between the sexes.
Postvaccination Fever and Antipyretics
The duration of postvaccination fever in children who were
administered antipyretics tended to be more prolonged than for
those who were not administered antipyretics in this study.
However, the actual body temperature at onset time and the
maximum temperature were significantly higher in children
who were administered antipyretics than in those who were not
administered antipyretics (mean 38.8, SD 0.6 vs mean 38.3, SD
0.5, respectively, P<.001). Therefore, it is possible that if the
period of decrease to the fever onset temperature (38°C) is
prolonged, antipyretics could be responsible for inhibiting the
immune response and extending the duration. It appears that
the use of antipyretic drugs influences the offset time rather
than the onset time, shortening the duration to offset time.
Antipyretics were associated with a trend toward prolonged
duration of illness in a group infected with Shigellasonnei and
the influenza virus [44,45]. A systematic review indicated that
the use of antipyretics in cases of malaria or viral diseases could
shorten the duration of fever without prolonging the course of
disease [38,39]. As noted, the effect of antipyretics on the course
of postvaccination fever remains inconclusive, and the effect
of antipyretics on postvaccination fever remains unknown.
Based on the results of this study, it is possible that antipyretic
use may prolong fever duration in children with postvaccination
fever.
According to surveys on the use of antipyretics for
postvaccination fever prevention and management by parents
and caregivers, 11% of parents administered antipyretics for
prophylaxis, and 64% of parents administered antipyretics for
prevention or management within 48 hours of vaccination [46].
Here, after vaccination, 14.66% of children were administered
their first antipyretic drugs within 1 hour and 16.2% of children
were administered antipyretics for fever with a body temperature
of less than 38°C (Figure 4). This value was higher than in
previous studies and may be due to (1) differences in data used
in the analysis, (2) cultural differences in the perception of fever,
and (3) relative underestimation due to recall bias arising from
retrospective survey methods used in prior studies. Also, many
parents and caregivers were administering antipyretics for
management of postvaccination fever when body temperatures
reached 38°C, most likely because the app instructions advised
parents not to administer antipyretics below a body temperature
of 38°C but rather to administer antipyretics when the body
temperature was above 38°C depending on the child’s condition.
Various studies have been conducted on the risks and benefits
of using antipyretics for postvaccination fever. Febrile
convulsions are the most worrying situation for parents and
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caregivers when fever is present. To prevent convulsions,
prophylactic antipyretics and routine antipyretics have been
used during fevers, but with no effect on reducing febrile
convulsions confirmed [23,39,47]. Additionally, several studies
have suggested that antipyretics may be associated with
decreased immunogenicity, and routine antipyretic
administration is no longer recommended for postvaccination
fever in countries such as Canada and New Zealand
[22,24,48-51]. Alternatively, a systematic review has shown
the difficulty of concluding that the reduction in immunogenicity
due to antipyretic use does not fall below the seroprotective
level and, thus, does not represent actual vaccine failure [48].
A high proportion of antipyretic use for postvaccination fever
is believed to be due to fever phobia and a parent’s expectation
that administering antipyretic drugs will ease a child’s
discomfort rather than being based on persuasive scientific
evidence [52]. Although antipyretic drugs had a temporary effect
in lowering body temperature for a mean of 4.4 hours, it is not
known whether their use reduced postvaccination fever-related
discomfort. To guide the use of antipyretics for alleviating
postvaccination fever-related discomfort based on scientific
evidence, the effects of antipyretics on fever patterns and child
discomfort need to be clarified through double-blinded
randomized clinical trials.
Limitations and Future Work
In our study, fever was defined as a body temperature above
38°C regardless of measurement method or age [53]. Although
in cases where rectal temperature measurements of 38°C or
above, or 1°C or more above basal body temperature, may be
defined as a fever [35,36], rectal temperature measurements are
not a readily applicable method of measuring body temperature,
and infrared tympanic thermometers, noncontact
infrared-forehead thermometers, axillary thermometers, and
oral thermometers are most commonly used in practice [54,55]
with inconsistent results [56-58]. Body temperature may also
vary depending on the age and biological factors of an
individual. The dataset used in this study did not contain any
information concerning the temperature measurement method
or site, and it was difficult to analyze all relevant factors
including age and biological factors in relation to temperature
measurement. Therefore, we defined a conservative standard
for fever as a body temperature greater than 38°C. This criterion
was consistent with the body temperature at which the child
was administered the antipyretic drug. A more accurate analysis
would be possible using a definition of fever as a body
temperature of 1°C above the basal body temperature or above
38°C, as well as obtaining the measurement method and site,
and acquiring mandatory data on basal body temperature.
Data used here were obtained by app users directly entering
their child’s body temperature. Since a uniform standard for
measuring body temperatures was not applied (including
measurement device and site), questions can be raised
concerning the accuracy of the body temperature data.
Furthermore, the app is dependent on the user entering the data
correctly and consistently.
Despite these limitations, the five vaccines included in this study
were more frequently recorded compared to the vaccines that
we excluded. It is possible that postvaccination fever is actually
more likely to occur due to these vaccines than others, and
parents may also have believed that postvaccination fever in
relation to these vaccines is more common than with others.
Therefore, they may have been more likely to perform body
temperature measurements. These limitations could be overcome
through wearing thermometers and body temperature recording
applications that continuously measure body temperatures before
and after vaccination.
In practice, multiple vaccinations are recommended rather than
single vaccinations, and more people are having multiple
vaccinations, since there are no challenges in obtaining
immunogenicity, no increase in side effects, and immunization
schedules can be simplified [59]. However, multiple
vaccinations may have an effect on postvaccination fever
patterns depending on vaccine types. This study focused on
single vaccinations; subsequent studies are underway concerning
multiple vaccinations.
In our study, an analysis of the use of antipyretic drugs was only
conducted after vaccination. However, the postvaccination fever
pattern can vary depending on when an antipyretic drug is
administered. More detailed research on postvaccination fever
patterns is needed to determine when an antipyretic drug is to
be administered.
Through creating a model that can predict future progress, based
on the natural course of postvaccination fever (Figure 6),
postvaccination temperature monitoring can provide useful
information to parents, caregivers, and health care professionals,
which is likely to reduce unnecessary tests and treatments, and
consequently contribute to improvements in children’s health.
Conclusion
Postvaccination fever has its own fever pattern depending on
the type of vaccine administered. The pattern of postvaccination
fever can be altered using antipyretic drugs, making the
diagnosis of postvaccination fever difficult. This study showed
that antipyretic drugs may prolong the duration of
postvaccination fever, due to routine use or overuse.
Postvaccination body temperature observation and comparison
with postvaccination fever patterns indicated here may reduce
the unnecessary use of antipyretics.
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